ReviewCurrent opinion in rheumatology2016
Treatment of catastrophic antiphospholipid syndrome.
Review in Current opinion in rheumatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 130 citations in OpenAlex.
- Antiphospholipid Antibody Syndrome and Cardiogenic Shock: A Fatal Intersection.JACC. Case reports · 2026Article
- Care of the Patient with Interstitial Lung Disease Perioperatively.Current rheumatology reports · 2026Review
- Emergency in pediatric rheumatology: a narrative review.Frontiers in medicine · 2026Review
- Intensive care unit admission and mortality in rheumatic diseases.Rheumatology international · 2025Review
- Article
- Catastrophic antiphospholipid syndrome presenting with a stroke as a first presentation: case report.Oxford medical case reports · 2025Article
- Case of severe thrombocytopenia with recurrent extensive deep vein thrombosis due to antiphospholipid syndrome, management challenge.Clinical case reports · 2025Article
- Mechanism of antiphospholipid antibody-mediated thrombosis in antiphospholipid syndrome.Frontiers in immunology · 2025Review
- Seronegative Catastrophic Antiphospholipid Syndrome: A Case Report of a Deadly Diagnosis.Cureus · 2024Article
- Catastrophic Antiphospholipid Syndrome in a Lupus Patient With Severe Recurrent Life-Threatening Clinical Manifestations.Journal of medical cases · 2024Article
- Catastrophic Antiphospholipid Syndrome: A Review of Current Evidence and Future Management Practices.Cureus · 2024Review
- Review
- Article
- Diagnosis and Management of Catastrophic Antiphospholipid Syndrome and the Potential Impact of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria.Antibodies (Basel, Switzerland) · 2024Review
- Challenges in Treating Extensive Deep Vein Thrombosis with Severe Thrombocytopenia in Patients with Antiphospholipid Syndrome-A Follow-up of 2 Years.The International journal of angiology : official publication of the International College of Angiology, Inc · 2024Article
- Primary catastrophic antiphospholipid syndrome in children with midbrain infarction: a case report.Frontiers in pediatrics · 2024Article
- Plasmapheresis in the ICU.Medicina (Kaunas, Lithuania) · 2023Review
- Article
- Article
- Antiphospholipid Syndrome in Renal Allograft Recipients-A Long-Term Multicenter Analysis.Journal of clinical medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewCatastrophic antiphospholipid syndrome (CAPS) is a severe manifestation of antiphospholipid syndrome (APS). Although affecting only 1% of patients with APS, the condition is frequently fatal if not recognized and treated early. Here, we will review the current approach to diagnosis and treatment of CAPS. RECENT
findingsData from the international 'CAPS registry', spearheaded by the European Forum on Antiphospholipid Antibodies, have improved our understanding of at-risk patients, typical clinical features, and precipitating diagnoses. Current guidelines also continue to support the role of anticoagulants and glucocorticoids as foundation therapy in all patients. Finally, new basic science and case series suggest that novel therapies, such as rituximab and eculizumab, warrant further study. SUMMARY: Attention to associated diagnoses, such as infection and systemic lupus erythematosus (SLE), is critical at the time of diagnosis. All patients should be treated with anticoagulants, corticosteroids, and possibly plasma exchange. In patients with SLE, cyclophosphamide should be considered. In refractory or relapsing cases, new therapies, such as rituximab and possibly eculizumab, may be options, but need further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.